Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the USPTO for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. The allowed claims encompass core methods and compositions fundamental to Anixa's innovative CAR-T approach, which is specifically designed to address challenges in applying CAR-T therapies to solid tumors.
The patent was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. The company's CAR-T technology is currently being tested in a clinical trial at Moffitt Cancer Center for treating recurrent ovarian cancer patients.
Anixa Biosciences (NASDAQ: ANIX) ha ricevuto un Avviso di Concessione dall'USPTO per una nuova domanda di brevetto che copre la sua tecnologia dei recettori antigenici chimerici per cellule T (CAR-T). Le rivendicazioni concesse comprendono metodi e composizioni fondamentali per l'approccio innovativo di Anixa alla tecnologia CAR-T, progettato specificamente per affrontare le sfide nell'applicazione delle terapie CAR-T ai tumori solidi.
Il brevetto è stato concesso al Wistar Institute ed è stato esclusivamente licenziato ad Anixa Biosciences. La tecnologia CAR-T dell'azienda è attualmente in fase di test in uno studio clinico presso il Moffitt Cancer Center per il trattamento di pazienti con cancro ovarico recidivante.
Anixa Biosciences (NASDAQ: ANIX) ha recibido un Aviso de Concesión de la USPTO para una nueva solicitud de patente que cubre su tecnología de receptores de antígenos quiméricos para células T (CAR-T). Las reivindicaciones aprobadas abarcan métodos y composiciones fundamentales para el enfoque innovador de Anixa en la tecnología CAR-T, diseñado específicamente para abordar los desafíos en la aplicación de terapias CAR-T a tumores sólidos.
La patente fue otorgada al Wistar Institute y se licenció exclusivamente a Anixa Biosciences. La tecnología CAR-T de la empresa se está probando actualmente en un ensayo clínico en el Moffitt Cancer Center para tratar a pacientes con cáncer de ovario recurrente.
Anixa Biosciences (NASDAQ: ANIX)는 키메라 항원 수용체-T 세포 (CAR-T) 기술에 대한 새로운 특허 신청에 대해 USPTO로부터 허가 통지를 받았습니다. 허가된 청구항은 Anixa의 혁신적인 CAR-T 접근 방식에 필수적인 핵심 방법 및 조성을 포함하며, 이는 CAR-T 치료를 고형 종양에 적용하는 데 있어 직면하는 문제를 해결하기 위해 특별히 설계되었습니다.
이 특허는 Wistar Institute에 부여되었으며 Anixa Biosciences에 독점 라이센스가 부여되었습니다. 회사의 CAR-T 기술은 현재 재발성 난소암 환자를 치료하기 위해 Moffitt Cancer Center에서 임상 시험 중입니다.
Anixa Biosciences (NASDAQ: ANIX) a reçu un Avis de Concession de l'USPTO pour une nouvelle demande de brevet couvrant sa technologie des récepteurs antigéniques chimériques pour cellules T (CAR-T). Les revendications autorisées englobent des méthodes et des compositions essentielles à l'approche innovante d'Anixa en matière de CAR-T, spécifiquement conçue pour relever les défis de l'application des thérapies CAR-T aux tumeurs solides.
Le brevet a été accordé à l'Institut Wistar et est exclusivement licencié à Anixa Biosciences. La technologie CAR-T de l'entreprise est actuellement testée dans un essai clinique au Moffitt Cancer Center pour le traitement de patientes atteintes de cancer de l'ovaire récurrent.
Anixa Biosciences (NASDAQ: ANIX) hat eine Erlaubnisbenachrichtigung vom USPTO für einen neuen Patentantrag erhalten, der ihre chimerische Antigenrezeptor-T-Zell (CAR-T) Technologie abdeckt. Die genehmigten Ansprüche umfassen grundlegende Methoden und Zusammensetzungen, die für Anixas innovative CAR-T-Ansatz entscheidend sind und speziell entwickelt wurden, um Herausforderungen bei der Anwendung von CAR-T-Therapien auf solide Tumoren zu bewältigen.
Das Patent wurde an das Wistar Institute vergeben und exklusiv an Anixa Biosciences lizenziert. Die CAR-T-Technologie des Unternehmens wird derzeit in einer klinischen Studie am Moffitt Cancer Center zur Behandlung von Patientinnen mit wiederkehrendem Eierstockkrebs getestet.
- Received USPTO Notice of Allowance for CAR-T technology patent
- Exclusive license agreement with The Wistar Institute
- Technology currently in clinical trials for ovarian cancer
- None.
The allowed claims in this patent encompass core methods and compositions that are fundamental to Anixa's innovative CAR-T approach. Anixa's CAR-T platform is specifically designed to address the long-standing challenges of applying CAR-T therapies to solid tumors, positioning the program as a potential breakthrough in immuno-oncology. This patent, along with others, was granted to The Wistar Institute and exclusively licensed to Anixa Biosciences. Anixa's CAR-T technology is currently in a clinical trial at Moffitt Cancer Center, treating recurrent ovarian cancer patients.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, stated, "This Notice of Allowance further strengthens our growing intellectual property portfolio and reinforces the potential of our robust CAR-T program. Securing foundational patent protection is a vital step in supporting the program's future success and in driving the development of next-generation immunotherapies with the potential to deliver transformative outcomes for patients."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. These vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-us-patent-and-trademark-office-for-car-t-technology-further-strengthening-its-robust-intellectual-property-portfolio-302427188.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the significance of Anixa's (ANIX) new patent allowance for CAR-T technology?
How is Anixa's (ANIX) CAR-T technology being currently tested?
Who owns the patent rights for Anixa's (ANIX) CAR-T technology?
What specific problem does Anixa's (ANIX) CAR-T technology address?
